Balyasny Asset Management
PTGX icon

Balyasny Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Balyasny Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,500
Closed -$1.99M – 3086
2024
Q2 		$1.99M Buy
+57,500
New +$1.68M ﹤0.01% 1534

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Balyasny Asset Management's PTGX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 96% in Q2 2026, selling an estimated $10.2M and leaving 3,598 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Balyasny Asset Management first reported a position in PTGX in Q1 2018 and has held it in 5 quarters since. The position peaked at $10.7M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Balyasny Asset Management held 3,598 shares of Protagonist Therapeutics worth $441K as of Q2 2026.
  • Balyasny Asset Management sold 97,701 Protagonist Therapeutics shares in Q2 2026, an estimated $10.2M.
  • Protagonist Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2577 holding.
  • Balyasny Asset Management first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • Balyasny Asset Management's Protagonist Therapeutics position peaked at $10.7M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.